AxioBiosolutions, that claims to be the first Indian company to get USFDA clearance for a wound care product, on Thursday said it has raised Rs 36 crore in Series B-1 round of funding led by Omidyar Network India, along with participation from existing investors.
The companys existing investors include Accel, University of California and Ratan Tatas UC-RNT Fund, ChirataeVentures.
The city based company, with its manufacturing plant in Ahmedabad, plans to use the latest funding to expand its footprint, especially in USA and Western Europe, Axio Biosolutions said in a release.
It said the company will continue to develop novel surgical and wound care products for global wound-care market
Disclaimer: No Business Standard Journalist was involved in creation of this content